Black Diamond Therapeutics (BDTX) Retained Earnings (2018 - 2026)
Black Diamond Therapeutics (BDTX) posted Retained Earnings of $578.1 million for Q1 2026, up 224.39% on a QoQ basis from -$464.7 million in Q4 2025, and up 234.26% year-over-year from $173.0 million in Q1 2025.
Black Diamond Therapeutics (BDTX) Retained Earnings (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics' Retained Earnings history runs 9 years deep, the most recent figure standing at $578.1 million for Q1 2026.
- Quarterly Retained Earnings rose 234.26% year-over-year to $578.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $578.1 million (up 234.26% YoY) and the FY2025 annual result came in at -$464.7 million, down 181.48% from the prior year.
- Retained Earnings was $578.1 million for Q1 2026 at Black Diamond Therapeutics, up from -$464.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at $578.1 million in Q1 2026 and bottomed at -$464.7 million in Q4 2025.
- A 5-year average of $9.4 million and a median of -$115000.0 in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings surged 2112548.15% — and 2025, when it sank 383487.83%.
- Black Diamond Therapeutics' Retained Earnings stood at $452.5 million in 2022, then tumbled by 100.01% to -$27000.0 in 2023, then jumped by 2112548.15% to $570.4 million in 2024, then slumped by 181.48% to -$464.7 million in 2025, then surged by 224.39% to $578.1 million in 2026.
- Business Quant data shows BDTX's Retained Earnings at $578.1 million in Q1 2026, -$464.7 million in Q4 2025, and $142000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | -27.89 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -279.01 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 12.91 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -622,000.00 |
| 10 | Black Diamond Therapeutics | 99.59 Mn | -18.67 Mn | - | 578.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 578.10 Mn |
| Dec 31, 2025 | -464.74 Mn |
| Sep 30, 2025 | 142,000.00 |
| Jun 30, 2025 | -441.13 Mn |
| Mar 31, 2025 | -430.60 Mn |
| Dec 31, 2024 | 570.36 Mn |
| Sep 30, 2024 | 568.43 Mn |
| Jun 30, 2024 | -115,000.00 |
| Mar 31, 2024 | -435.66 Mn |
| Dec 31, 2023 | -27,000.00 |
| Sep 30, 2023 | -398.02 Mn |
| Jun 30, 2023 | -375.02 Mn |
| Mar 31, 2023 | -355.86 Mn |
| Dec 31, 2022 | 452.50 Mn |
| Sep 30, 2022 | 449.63 Mn |
| Jun 30, 2022 | -2.29 Mn |
| Mar 31, 2022 | 443.66 Mn |
| Dec 31, 2021 | 440.13 Mn |
| Sep 30, 2021 | 436.75 Mn |
| Jun 30, 2021 | 211,000.00 |